Evidence map›Paper›PMID 39899790›Full record

Observational studyNeurology2025

Longitudinal Cognitive Changes in Cerebral Small Vessel Disease: The Effect of White Matter Hyperintensity Regression and Progression.

Angela C C Jochems, Susana Muñoz Maniega, Una Clancy, Carmen Arteaga-Reyes, Daniela Jaime Garcia, Francesca M Chappell, Olivia K L Hamilton, Ellen V Backhouse, Gayle Barclay, Charlotte Jardine and 10 more

Abstract readObservational Study
In one paragraph

Observational study in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The enigma of vascular dementia: current state and emerging perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Angela C C JochemsCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0001-7392-3066
Susana Muñoz ManiegaCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0001-5185-6384
Una ClancyCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0002-8062-7537
Carmen Arteaga-ReyesCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0003-2424-7123
Daniela Jaime GarciaCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0002-9457-9855
Francesca M ChappellCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0002-7742-1757
Olivia K L HamiltonMRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, United Kingdom; and.ORCID 0000-0002-5874-0058
Ellen V BackhouseCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.
Gayle BarclayEdinburgh Imaging Facility, Royal Infirmary of Edinburgh, United Kingdom.
Charlotte JardineEdinburgh Imaging Facility, Royal Infirmary of Edinburgh, United Kingdom.
Donna McIntyreEdinburgh Imaging Facility, Royal Infirmary of Edinburgh, United Kingdom.
Iona HamiltonEdinburgh Imaging Facility, Royal Infirmary of Edinburgh, United Kingdom.ORCID 0009-0005-1308-3380
Eleni SakkaCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.
Maria Del C Valdés HernándezCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0003-2771-6546
Stewart WisemanCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0001-6739-5797
Mark E BastinCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0002-0490-0845
Michael S StringerCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0002-3811-4439
Michael ThrippletonCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0001-7858-9917
Fergus DoubalCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0002-2769-3148
Joanna M WardlawCentre for Clinical Brain Sciences, University of Edinburgh, United Kingdom.ORCID 0000-0002-9812-6642

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesWhite matter hyperintensities (WMHs) are the commonest imaging marker of cerebral small vessel disease (SVD) and a major cause of cognitive decline and vascular dementia. WMHs typically accumulate over time, but recent studies show they can also regress, but potential clinical benefits have received little attention. We examined progressing, stable, and regressing WMH in people with stroke-related SVD and the effect on cognitive outcomes.

methodsWe recruited patients with minor nondisabling ischemic stroke (modified Rankin score ≤2) from stroke services into our prospective longitudinal observational study. Participants underwent cognitive assessment and brain MRI within 3-month poststroke and 1 year later. We gathered information on vascular risk factors, stroke severity, global cognition (Montreal Cognitive Assessment [MoCA]), processing speed and executive functioning (Trail Making Test [TMT] A and B, and the B/A ratio with ratio ≥3 reflecting executive dysfunction), and the Letter Digit Substitution Test. We measured WMH volumes at baseline and 1 year and categorized net WMH volume change into quintiles: Q1 (most regression), Q3 (stable), and Q5 (most progression). We applied repeated-measures linear mixed models to analyze longitudinal WMH and cognitive changes, adjusting for age, sex, premorbid intelligence, stroke severity, disability, white matter structural integrity, and baseline WMH volume.

resultsOne hundred ninety-eight of 229 participants had WMH volumes available at both time-points. At baseline, the mean age was 67.5 years (SD = 10.9), with 33% female. Mean net WMH volume change per quintile was Q1 -1.79 mL (SD = 1.54), Q2 -0.27 mL (0.20), Q3 0.35 mL (0.18), Q4 1.43 mL (0.48), and Q5 5.31 mL (3.07). MoCA deteriorated the most in participants with most WMH progression (Q5) (estimated β -0.428 [95% CI -0.750 to -0.106]), compared with stable WMH (Q3), with no clear deterioration in those with most WMH regression (Q1). TMT B/A ratio improved in participants with most WMH regression (Q1; -0.385 [-0.758 to -0.012]). DISCUSSION: WMH regression was associated with preserved global cognition and improved executive function, compared with stable WMH, while WMH progression was associated with global cognitive decline. Cognitive benefits of WMH regression suggest that WMH-affected tissue can recover, may explain variance in cognitive outcomes, offer an important intervention target, and should be assessed in other populations and longer follow-up times.

Indexed as

Cerebral Small Vessel DiseasesCognitive DysfunctionWhite MatterAgedAged, 80 and overDisease ProgressionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsProspective Studies

Identifiers

PMID39899790
PMCPMC11793922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.